ZTS Stock Recent News

Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness

Zoetis is the world's largest producer of medicine and vaccinations for pets and livestock. It's also been incredibly profitable for its shareholders since its spinoff from Pfizer.

Kristin Peck, Zoetis CEO, joins 'Money Movers' to discuss what Zoetis' guidance says about Peck's business expectations, factors that are contributing to their growth relative to fundamentals, and how consumers are thinking about their pets.

Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.

The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zoetis (ZTS) came out with quarterly earnings of $1.24 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $1.15 per share a year ago.

Beyond analysts' top -and-bottom-line estimates for Zoetis (ZTS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zoetis CFO Wetteny Joseph discusses growth in the animal health care sector.